IN2014DN08582A - - Google Patents
Info
- Publication number
- IN2014DN08582A IN2014DN08582A IN8582DEN2014A IN2014DN08582A IN 2014DN08582 A IN2014DN08582 A IN 2014DN08582A IN 8582DEN2014 A IN8582DEN2014 A IN 8582DEN2014A IN 2014DN08582 A IN2014DN08582 A IN 2014DN08582A
- Authority
- IN
- India
- Prior art keywords
- diabetes mellitus
- relates
- type
- hyperglycemia
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644721P | 2012-05-09 | 2012-05-09 | |
US201261645787P | 2012-05-11 | 2012-05-11 | |
PCT/EP2013/059423 WO2013167554A1 (en) | 2012-05-09 | 2013-05-07 | Pharmaceutical combinations for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN08582A true IN2014DN08582A (xx) | 2015-05-22 |
Family
ID=48485118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN8582DEN2014 IN2014DN08582A (xx) | 2012-05-09 | 2013-05-07 |
Country Status (18)
Country | Link |
---|---|
US (3) | US20130303446A1 (xx) |
EP (1) | EP2846797A1 (xx) |
JP (1) | JP2015516404A (xx) |
KR (1) | KR20150014488A (xx) |
CN (1) | CN104427985A (xx) |
AR (1) | AR090999A1 (xx) |
AU (1) | AU2013258109A1 (xx) |
BR (1) | BR112014027884A2 (xx) |
CA (1) | CA2872932A1 (xx) |
CL (1) | CL2014002978A1 (xx) |
EA (1) | EA201401231A1 (xx) |
IL (1) | IL235058A0 (xx) |
IN (1) | IN2014DN08582A (xx) |
MX (1) | MX2014013452A (xx) |
PH (1) | PH12014502448A1 (xx) |
TW (1) | TW201406374A (xx) |
UY (1) | UY34800A (xx) |
WO (1) | WO2013167554A1 (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10383580B2 (en) * | 2012-12-31 | 2019-08-20 | Abbott Diabetes Care Inc. | Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
DK3207928T3 (da) | 2014-10-17 | 2021-04-26 | Hyundai Pharm Co Ltd | Sammensat præparat, der indeholder hidtil ukendt 3-(4-(benzyloxy)phenyl)hex-4-inonsyrederivat og en anden aktiv bestanddel, til forebyggelse eller behandling af metaboliske sygdomme |
EP3463330B1 (en) * | 2016-06-02 | 2022-05-04 | Syndromex Ltd. | Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates |
KR102444366B1 (ko) * | 2016-06-03 | 2022-09-19 | 케모센트릭스, 인크. | 간 섬유화 치료 방법 |
CN109640993B (zh) * | 2016-08-12 | 2021-07-09 | 诺麦塔制药有限公司 | 包含阿莫地喹及抗糖尿病药物作为有效成分的用于预防或治疗糖尿病的药学组合物 |
NL2019605B1 (en) * | 2017-09-22 | 2019-03-28 | Cfm Pharma Holding B V | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement |
CN110652498B (zh) * | 2019-11-22 | 2022-04-05 | 河南合智医药科技有限公司 | 一种用于治疗2型糖尿病的药物制剂及其制备方法 |
CN112220768A (zh) * | 2020-10-15 | 2021-01-15 | 四川维奥制药有限公司 | 一种米格列醇片剂的制备方法 |
WO2024055932A1 (zh) * | 2022-09-13 | 2024-03-21 | 亚宝药业集团股份有限公司 | 氮杂环化合物、其药物组合物和用于预防和/或治疗疾病的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
CA2557801C (en) | 2004-03-16 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
UA91546C2 (xx) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-$4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ$КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(b-D-ГЛЮКОПИРАНОЗ-1- ИЛ)-2-$4-((S)- ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ ПРИ ПРИГОТАВЛЕНИИ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
WO2008020011A1 (en) | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
WO2008055870A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
UY33001A (es) * | 2009-11-06 | 2011-05-31 | Boehringer Ingelheim Int | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina |
TWI537258B (zh) * | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物 |
-
2013
- 2013-05-07 US US13/888,602 patent/US20130303446A1/en not_active Abandoned
- 2013-05-07 AU AU2013258109A patent/AU2013258109A1/en not_active Abandoned
- 2013-05-07 CN CN201380023728.XA patent/CN104427985A/zh active Pending
- 2013-05-07 JP JP2015510776A patent/JP2015516404A/ja active Pending
- 2013-05-07 IN IN8582DEN2014 patent/IN2014DN08582A/en unknown
- 2013-05-07 WO PCT/EP2013/059423 patent/WO2013167554A1/en active Application Filing
- 2013-05-07 CA CA2872932A patent/CA2872932A1/en not_active Abandoned
- 2013-05-07 KR KR1020147034475A patent/KR20150014488A/ko not_active Application Discontinuation
- 2013-05-07 MX MX2014013452A patent/MX2014013452A/es unknown
- 2013-05-07 EA EA201401231A patent/EA201401231A1/ru unknown
- 2013-05-07 EP EP13724752.4A patent/EP2846797A1/en not_active Withdrawn
- 2013-05-07 BR BR112014027884A patent/BR112014027884A2/pt not_active IP Right Cessation
- 2013-05-08 TW TW102116415A patent/TW201406374A/zh unknown
- 2013-05-08 AR ARP130101606A patent/AR090999A1/es unknown
- 2013-05-09 UY UY0001034800A patent/UY34800A/es unknown
-
2014
- 2014-09-05 US US14/478,368 patent/US20140378398A1/en not_active Abandoned
- 2014-10-07 IL IL235058A patent/IL235058A0/en unknown
- 2014-11-03 CL CL2014002978A patent/CL2014002978A1/es unknown
- 2014-11-03 PH PH12014502448A patent/PH12014502448A1/en unknown
-
2015
- 2015-11-18 US US14/944,249 patent/US20160067227A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20150014488A (ko) | 2015-02-06 |
EA201401231A1 (ru) | 2015-08-31 |
EP2846797A1 (en) | 2015-03-18 |
CA2872932A1 (en) | 2013-11-14 |
TW201406374A (zh) | 2014-02-16 |
CN104427985A (zh) | 2015-03-18 |
IL235058A0 (en) | 2014-12-31 |
WO2013167554A1 (en) | 2013-11-14 |
MX2014013452A (es) | 2014-12-08 |
PH12014502448A1 (en) | 2015-01-12 |
BR112014027884A2 (pt) | 2017-06-27 |
US20160067227A1 (en) | 2016-03-10 |
US20130303446A1 (en) | 2013-11-14 |
JP2015516404A (ja) | 2015-06-11 |
AU2013258109A1 (en) | 2014-10-30 |
AR090999A1 (es) | 2014-12-30 |
CL2014002978A1 (es) | 2015-03-13 |
UY34800A (es) | 2013-11-29 |
US20140378398A1 (en) | 2014-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN08582A (xx) | ||
PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
MY174002A (en) | Combination theraphy for the treatment of diabetes | |
TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
IN2012DN01233A (xx) | ||
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
UA102429C2 (ru) | Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
MX2013003034A (es) | Lactamas piperidinilo-substituidas como moduladores de gpr119. | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
IN2014MN02380A (xx) | ||
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
MY156174A (en) | 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity | |
MX2012006287A (es) | Activadores de azaindol glucocinasa. | |
MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
MX338438B (es) | Derivados de isoindolinona. |